Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 25, 2017January 25, 2017

Seeing How a Protein Works to Control B-cell Metabolism May Aid in Treating Lymphoma

News

B-cells have a protein that controls their metabolism — allowing them to adapt and work differently depending on where they are in the body, whether the spleen, lymph nodes or ... Read more

January 18, 2017

Three-Drug Combination Shows Promise for Treating Mantle Cell Lymphoma

News

A combination of Rituxan (rituximab), Revlimid (lenalidomide), and Bendeka (bendamustine) (R2B) may be a viable option for treating relapsed or treatment-resistant mantle cell lymphoma, a study suggested. A Phase 2 ... Read more

January 6, 2017

Proteins Mutated in Lymphoma Control Normal T-cell Development, Study Finds

News

Proteins that are often mutated in T-cell lymphomas are crucial for normal T-cell development, researchers have discovered. Mice lacking the factors developed an abnormal T-cell type that gave rise to ... Read more

January 5, 2017

Study Links 2 Inherited Mutations to Risk of Cutaneous T-Cell Lymphoma

News

Mutations in two genes coding for the immune cytokines IL-2 and IL-13 increase the risk of cutaneous T-cell lymphoma (CTCL), researchers have found, while mutations in two other immune factors ... Read more

December 9, 2016December 9, 2016

Gazyva Shown to Outperform Rituxan in Phase 3 Trial in Follicular Lymphoma Patients

News

Patients with follicular lymphoma may soon have a new treatment option, as Genentech recently demonstrated that Gazyva (obinutuzumab) improved survival times without disease progression compared to standard treatment with Rituxan (rituximab). ... Read more

November 17, 2016

Inactive Autoimmune B-cells May Play Role in Lymphoma Development

News

New insights into the immunologic role of a specific type of B-cells — capable of autoimmune reactions but held in lockdown — may advance the understanding of how these cells ... Read more

November 16, 2016November 16, 2016

Lymphoma DNA in Blood Offers Easy Access to Treatment, Relapse, Prognosis Insights

News

Bits of cancer DNA circulating in the blood of lymphoma patients can provide physicians with information on the cancer subtype and identify mutations linked to treatment resistance. The findings bring ... Read more

November 1, 2016

Lymphoma Genetic Studies Should Skip Reference Genomes, Use Same Healthy Cells as Controls, Researchers Say

News

Many of the most important discoveries happen by chance. This was the case when researchers discovered that comparing mice lymphoma genome sequences to a reference genome is like comparing apples ... Read more

October 27, 2016October 27, 2016

New Report Supports Opdivo for Relapsed Hodgkin’s Lymphoma Patients

News

Bristol-Myers Squibb recently presented data supporting the use of Opdivo (nivolumab) in a subgroup of patients with classical Hodgkin’s lymphoma who had undergone a prior stem cell transplant and treatment with ... Read more